Cargando…

Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study

BACKGROUND: Respiratory complications are the most important cause of morbidity and mortality in spinal muscular atrophy (SMA). Respiratory muscle weakness results in impaired cough, recurrent respiratory tract infections and eventually can cause respiratory failure. We assessed longitudinal pattern...

Descripción completa

Detalles Bibliográficos
Autores principales: Veldhoen, Esther S., Wijngaarde, Camiel A., Hulzebos, Erik H. J., Wösten-van Asperen, Roelie M., Wadman, Renske I., van Eijk, Ruben P. A., Asselman, Fay Lynn, Stam, Marloes, Otto, Louise A. M., Cuppen, Inge, Scheijmans, Feline E. V., den Oudenrijn, Laura P. Verweij-van, Bartels, Bart, Gaytant, Michael A., van der Ent, Cornelis K., van der Pol, W. Ludo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862532/
https://www.ncbi.nlm.nih.gov/pubmed/35189949
http://dx.doi.org/10.1186/s13023-022-02227-7
_version_ 1784655072291979264
author Veldhoen, Esther S.
Wijngaarde, Camiel A.
Hulzebos, Erik H. J.
Wösten-van Asperen, Roelie M.
Wadman, Renske I.
van Eijk, Ruben P. A.
Asselman, Fay Lynn
Stam, Marloes
Otto, Louise A. M.
Cuppen, Inge
Scheijmans, Feline E. V.
den Oudenrijn, Laura P. Verweij-van
Bartels, Bart
Gaytant, Michael A.
van der Ent, Cornelis K.
van der Pol, W. Ludo
author_facet Veldhoen, Esther S.
Wijngaarde, Camiel A.
Hulzebos, Erik H. J.
Wösten-van Asperen, Roelie M.
Wadman, Renske I.
van Eijk, Ruben P. A.
Asselman, Fay Lynn
Stam, Marloes
Otto, Louise A. M.
Cuppen, Inge
Scheijmans, Feline E. V.
den Oudenrijn, Laura P. Verweij-van
Bartels, Bart
Gaytant, Michael A.
van der Ent, Cornelis K.
van der Pol, W. Ludo
author_sort Veldhoen, Esther S.
collection PubMed
description BACKGROUND: Respiratory complications are the most important cause of morbidity and mortality in spinal muscular atrophy (SMA). Respiratory muscle weakness results in impaired cough, recurrent respiratory tract infections and eventually can cause respiratory failure. We assessed longitudinal patterns of respiratory muscle strength in a national cohort of treatment-naïve children and adults with SMA, hypothesizing a continued decline throughout life. METHODS: We measured maximal expiratory and inspiratory pressure (PE(max) and PI(max)), Sniff Nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), and peak cough flow (PCF) in treatment-naïve patients with SMA. We used mixed-models to analyze natural history patterns. RESULTS: We included 2172 measurements of respiratory muscle function from 80 treatment-naïve patients with SMA types 1c-3b. All outcomes were lower in the more severe phenotypes. Significant differences in PEF were present between SMA types from early ages onwards. PEF decline was linear (1–2%/year). PEF reached values below 80% during early childhood in types 1c-2, and during adolescence in type 3a. PE(max) and PI(max) were severely lowered in most patients throughout life, with PE(max) values abnormally low (i.e. < 80 cmH(2)O) in virtually all patients. The PE(max)/PI(max) ratio was < 1 throughout life in all SMA types, indicating that expiratory muscles were most affected. All but SMA type 3b patients had a lowered PCF. Patients with types 2b and 3a had PCF levels between 160 and 270 L/min, those with type 2a around 160 L/min and patients with type 1c well below 160 L/min. Finally, SNIP was low in nearly all patients, most pronounced in more severely affected patients. CONCLUSIONS: There are clear differences in respiratory muscle strength and its progressive decline between SMA types. We observed lower outcomes in more severe SMA types. Particularly PEF may be a suitable outcome measure for the follow-up of respiratory strength in patients with SMA. PEF declines in a rather linear pattern in all SMA types, with clear differences at baseline. These natural history data may serve as a reference for longer-term treatment efficacy assessments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-022-02227-7.
format Online
Article
Text
id pubmed-8862532
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88625322022-02-23 Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study Veldhoen, Esther S. Wijngaarde, Camiel A. Hulzebos, Erik H. J. Wösten-van Asperen, Roelie M. Wadman, Renske I. van Eijk, Ruben P. A. Asselman, Fay Lynn Stam, Marloes Otto, Louise A. M. Cuppen, Inge Scheijmans, Feline E. V. den Oudenrijn, Laura P. Verweij-van Bartels, Bart Gaytant, Michael A. van der Ent, Cornelis K. van der Pol, W. Ludo Orphanet J Rare Dis Research BACKGROUND: Respiratory complications are the most important cause of morbidity and mortality in spinal muscular atrophy (SMA). Respiratory muscle weakness results in impaired cough, recurrent respiratory tract infections and eventually can cause respiratory failure. We assessed longitudinal patterns of respiratory muscle strength in a national cohort of treatment-naïve children and adults with SMA, hypothesizing a continued decline throughout life. METHODS: We measured maximal expiratory and inspiratory pressure (PE(max) and PI(max)), Sniff Nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), and peak cough flow (PCF) in treatment-naïve patients with SMA. We used mixed-models to analyze natural history patterns. RESULTS: We included 2172 measurements of respiratory muscle function from 80 treatment-naïve patients with SMA types 1c-3b. All outcomes were lower in the more severe phenotypes. Significant differences in PEF were present between SMA types from early ages onwards. PEF decline was linear (1–2%/year). PEF reached values below 80% during early childhood in types 1c-2, and during adolescence in type 3a. PE(max) and PI(max) were severely lowered in most patients throughout life, with PE(max) values abnormally low (i.e. < 80 cmH(2)O) in virtually all patients. The PE(max)/PI(max) ratio was < 1 throughout life in all SMA types, indicating that expiratory muscles were most affected. All but SMA type 3b patients had a lowered PCF. Patients with types 2b and 3a had PCF levels between 160 and 270 L/min, those with type 2a around 160 L/min and patients with type 1c well below 160 L/min. Finally, SNIP was low in nearly all patients, most pronounced in more severely affected patients. CONCLUSIONS: There are clear differences in respiratory muscle strength and its progressive decline between SMA types. We observed lower outcomes in more severe SMA types. Particularly PEF may be a suitable outcome measure for the follow-up of respiratory strength in patients with SMA. PEF declines in a rather linear pattern in all SMA types, with clear differences at baseline. These natural history data may serve as a reference for longer-term treatment efficacy assessments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-022-02227-7. BioMed Central 2022-02-21 /pmc/articles/PMC8862532/ /pubmed/35189949 http://dx.doi.org/10.1186/s13023-022-02227-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Veldhoen, Esther S.
Wijngaarde, Camiel A.
Hulzebos, Erik H. J.
Wösten-van Asperen, Roelie M.
Wadman, Renske I.
van Eijk, Ruben P. A.
Asselman, Fay Lynn
Stam, Marloes
Otto, Louise A. M.
Cuppen, Inge
Scheijmans, Feline E. V.
den Oudenrijn, Laura P. Verweij-van
Bartels, Bart
Gaytant, Michael A.
van der Ent, Cornelis K.
van der Pol, W. Ludo
Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
title Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
title_full Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
title_fullStr Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
title_full_unstemmed Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
title_short Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
title_sort natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862532/
https://www.ncbi.nlm.nih.gov/pubmed/35189949
http://dx.doi.org/10.1186/s13023-022-02227-7
work_keys_str_mv AT veldhoenesthers naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT wijngaardecamiela naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT hulzeboserikhj naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT wostenvanasperenroeliem naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT wadmanrenskei naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT vaneijkrubenpa naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT asselmanfaylynn naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT stammarloes naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT ottolouiseam naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT cuppeninge naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT scheijmansfelineev naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT denoudenrijnlaurapverweijvan naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT bartelsbart naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT gaytantmichaela naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT vanderentcornelisk naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy
AT vanderpolwludo naturalhistoryofrespiratorymusclestrengthinspinalmuscularatrophyaprospectivenationalcohortstudy